Galmed Pharma (NASDAQ: GLMD) reported Q3 EPS of ($0.23), $0.03 better than the analyst estimate of ($0.26). Revenue for the quarter came in at $300 thousand versus the consensus estimate of $330 thousand.

For earnings history and earnings-related data on Galmed Pharma (GLMD) click here.